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Co-prescription of co-trimoxazole and spironolactone
in elderly patients
The combination should be used with caution because of the risk of hyperkalaemia
Li Wei lecturer, Thomas M MacDonald professor , Isla S Mackenzie clinical senior lecturer
Medicines Monitoring Unit (MEMO) and Hypertension Research Centre (HRC), Division of Medical Sciences, University of Dundee, Ninewells
Hospital and Medical School, Dundee DD1 9SY, UK
Although much effort goes into understanding the risks and
benefits of recently licensed drugs, less is known about many
of the older drugs that are prescribed widely. For example, the
phrase “safe as aspirin” is often used to extol the safety virtues
of a drug, even though aspirin is one of the main culprits when
it comes to hospital admissions related to an adverse drug event.1
Spironolactone and trimethoprim-sulfamethoxazole
(co-trimoxazole) are two “older” drugs about which we should
know more. In the linked case-control study (doi:10.1136/bmj.
d5228), Antoniou and colleagues assess the risk of admission
to hospital for hyperkalaemia in elderly patients treated with
co-trimoxazole in combination with spironolactone.2
Spironolactone works well in congestive heart failure,3 resistant
hypertension,4 hyperaldosteronism,5 and hypertension in
general.6 Despite hypertension being an unlicensed indication
in the United Kingdom, the new guidelines from the National
Institute for Health and Clinical Excellence (NICE) on
hypertension name spironolactone as an option for fourth line
treatment.7 Because of these benefits, the use of spironolactone
in the UK and elsewhere has increased greatly over recent years,
mainly for the above indications, but also for secondary
aldosteronism resulting from cirrhotic liver disease.8
The down side of spironolactone is the risk of hyperkalaemia,
which is increased in older people; those with renal impairment,
diabetes, or a high pretreatment serum potassium; and when it
is co-administered with potassium supplements and drugs that
reduce potassium excretion. Hyperkalaemia with spironolactone
has been reported in patients with congestive heart failure,9 but
this has not been a major problem in the UK because of the
cautious prescribing and frequent monitoring of renal function
within the NHS.8 The more selective aldosterone antagonist,
eplerenone, may be less toxic than spironolactone, but it is also
less effective, at least in patients with hypertension and
aldosteronism.10
In Canada, co-trimoxazole is the most commonly prescribed
antibiotic for urinary tract infection. This is unlike the UK,
where the use of co-trimoxazole is restricted because of concerns
about serious cutaneous adverse reactions and blood dyscrasias.
In the UK, trimethoprim, a component of co-trimoxazole, is
much more commonly used for this indication. Hyperkalaemia
is also a risk with co-trimoxazole, probably because of the
potassium sparing action of trimethoprim.
Given the benefits and potential for toxicity with spironolactone
and trimethoprim or co-trimoxazole, any new data that will
inform the risk-benefit balance of these drugs are welcome.
Antoniou and colleagues’ study shows an important adverse
pharmacodynamic interaction between co-trimoxazole and
spironolactone in elderly patients that can lead to hospital
admission for hyperkalaemia—a relatively “hard” biochemical
end point. There was also a smaller risk of hyperkalaemia with
co-prescription of nitrofurantoin. The same authors have
previously reported serious hyperkalaemia associated with
co-prescription of co-trimoxazole and angiotensin converting
enzyme inhibitors or angiotensin receptor blockers (adjusted
odds ratio 6.7, 95% confidence interval 4.5 to 10.0), which is
thought to be caused by a similar pharmacodynamic interaction.11
In the current study, Antoniou and colleagues reported that
patients taking spironolactone and co-trimoxazole were about
12 times more likely to be admitted to hospital for
hyperkalaemia (12.4, 7.1 to 21.6) than those taking
spironolactone with amoxicillin.2 The risks of co-trimoxazole
were also dose related. The population attributable fraction
suggests that around 60% of admissions to hospital for
hyperkalaemia in elderly patients taking spironolactone and an
antibiotic for a urinary tract infection could be avoided if
co-trimoxazole was not co-prescribed with spironolactone.
As with all observational studies, various factors might confound
the outcomes of interest because of the co-linearity of some
variables in the study. However, the greatly increased risk
(around 12-fold) suggests that minor problems with data
adjustments would not have changed the overall finding of an
increased risk of hyperkalaemia for co-prescribing
co-trimoxazole and spironolactone.
To set the results in a UK context, trimethoprim is prescribed
to about 60 per 1000 of the UK population each year,
co-trimoxazole to 0.8 per 1000, nitrofurantoin to 18 per 1000,
and spironolactone to 7 per 1000 (data for 2010 from theMEMO
database12). The co-prescription of spironolactone with
trimethoprim is therefore likely to occur infrequently but is set
to increase as spironolactone is used more often and broad
spectrum antibiotics for urinary tract infection are avoided to
mitigate the development of Clostridium difficile colitis.
We need to know if trimethoprim alone will cause a similar
adverse drug interaction as co-trimoxazole (as seems likely),
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whether these risks extend to younger people, and whether other
factors increase the risks. So, as always, more research is needed.
In the interim, a cautious approach is needed and the use of
alternative antibiotics should be considered where appropriate.
Monitoring for hyperkalaemia should be increased, and
temporarily reducing the dose of spironolactone or angiotensin
converting enzyme inhibitors or angiotensin receptor blockers
might be useful in patients receiving these drugs in combination
with trimethoprim, co-trimoxazole, or even (until further data
are available) nitrofurantoin.
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